Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06216756

Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee

The primary objective of this study is to obtain evidence of the effectiveness of Cryopreserved Osteochondral Allograft Core in the treatment of osteochondral lesions on the femoral condyle.

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Banner- University Medical Center- Phoenix Orthopedic and Sports Medicine Institute, Phoenix, Arizona, United States

Loading trial locations.

About this study

Patients between the ages of ≥12 years and ≤ 60 years who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 0.9-8.0 cm2 in size, and cystic changes requiring osseous repair, as confirmed by MRI , CT scan, or arthroscopy, and undergoing an osteochondral transplant procedure will be eligible for enrollment. Patients will receive one or more cryopreserved osteochondral allograft core transplants to replace damaged cartilage.

Patients will be followed for up to 60 months post-procedure (6 weeks, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months) to evaluate short and long-term outcomes of the procedure using the cryopreserved osteochondral allograft cores.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients are ≥12 years and ≤ 60 years of age at the time of surgery.
  • Symptomatic patient presenting with moderate to severe pain in the index knee - unresponsive to conservative treatment (i.e., medication, bracing, physical therapy) and/or previous surgical intervention OR unsalvageable lesion that requires transplantation at the discretion of the treating physician.
  • Radiographically diagnosed, by MRI or CT scans, or through arthroscopy, to have a cartilage defect on the femoral condyle between 0.9-8.0 cm2 in size.
  • Will be having an osteochondral transplant procedure.
  • Has a mechanically stable knee or can be mechanically stabilized in the same procedure.
  • Has a normally aligned knee as confirmed by anatomic comparison to contralateral limb, or <5° varus or valgus malalignment that has been corrected or will be corrected in same procedure.
  • Ipsilateral knee compartment has intact menisci or requires partial meniscectomy ≤ 50% resulting in stable menisci.
  • Confirmation MRI, CT scan, or arthroscopy obtained pre-operatively within 90 days of surgery
  • Willingness to follow standardized rehabilitation procedures.
  • Has the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.

Exclusion criteria

  • Bipolar articular cartilage involvement (kissing lesions) of the ipsilateral compartment (i.e., > than ICRS Grade 2 on the opposing articular surface).
  • Has had a prior osteochondral allograft transplant procedure in the same knee.
  • Will be receiving a meniscus allograft transplantation in the same procedure.
  • Body Mass Index (BMI)of ≥ 35 kg/m2.
  • Active malignancy: undergoing treatment for tumor or boney traumatic injury or a history of any invasive malignancy (except non-melanoma skin cancer) unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.
  • Clinical and/or radiographic disease in the affected joint that includes generalized osteoarthritis, gout or a history of gout or pseudo-gout.
  • Active local microbial infection or a systemic infection, including HIV, syphilis, Hepatitis B or Hepatitis C.
  • Currently immunologically suppressed or immunocompromised, or a medical condition requiring radiation and/or chemotherapy.
  • Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer, or uncontrolled diabetes.
  • Has a history of any inflammatory joint arthropathy.
  • Currently using/chronic on oral corticosteroids.
  • Received interarticular corticosteroid injection ≤ 90 days prior to surgery.
  • Received hyaluronic acid injections into the joint space ≤ 45 days prior to surgery.
  • Is a female patient who is pregnant.
  • Physically or mentally compromised (i.e., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his/her ability to participate in the clinical study.
  • Has a history of substance abuse- (including but not limited to recreational drugs, alcohol) or has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an in-patient substance abuse program.
  • Patients who, in the opinion of the Investigator, would not be able or willing to comply with the protocol.
  • Is currently involved in a study of another investigational product for similar purpose or has been in the previous 90 days.
  • Has any contraindications for MRI.
  • Is having the procedure as part of a Worker's Compensation claim.
  • Is a ward of the state, prisoner, or transient.

Treatment and study plan

osteochondral transplant on the femoral condyle

Procedure

Patients between the ages of ≥12 years and ≤ 60 years who have a symptomatic full-thickness cartilage lesion (Grade 3 or 4) on the femoral condyle, in a mechanically stable knee, or is being mechanically stabilized in the same procedure, between 0.9-8.0 cm2 in size, and cystic changes requiring osseous repair, as confirmed by MRI , CT scan, or arthroscopy and will undergo a osteochondral transplant by removing the damaged cartilage and replacing that cartilage with a cryopreserved osteochondral allograft core.

Primary outcomes

  1. International Knee Documentation Committee (IKDC) score

    Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months post procedure

    Change of physical functioning and pain from baseline as assessed by the subjective International Knee Documentation Committee (IKDC) score.

    Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.

Secondary outcomes

  1. Knee Injury and Osteoarthritis Outcome Score (KOOS)

    Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

    Change from baseline (pre-operative)

    Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.

  2. Assessment of repair cartilage structure

    Time frame: 12 months, 24 months and 60 months post procedure

    Assessment of repair cartilage structure, using Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores, as measured by Magnetic Resonance Imaging (MRI).

    Scores are reported on a 0-100 scale, with low scores indicating worse outcomes and higher scores indicating better outcomes.

  3. Graft incorporation

    Time frame: 12 months, 24 months and 60 months post procedure

    Assessment of graft incorporation using Magnetic Resonance Imaging (MRI)

  4. 12-item Veterans RAND (VR-12)

    Time frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months post procedure

    Change from baseline (pre-operative)

    The instrument is primarily used to measure health related quality of life, to estimate disease burden and to evaluate disease-specific benchmarks with other populations. The 12 items are summarized into two scores, a "Physical Health Summary Measure" and a "Mental Health Summary Measure."

  5. Revision surgery

    Time frame: 60 months post-procedure

    Incidences of revision surgeries during study follow up time period

Study contacts

Contact information is provided by the study sponsor or research team.

Elizabeth Esterl, DNP, MS, RN

CONTACT

[email protected]

7207326231

Paige McHenry, MS, ATC, CCRA

CONTACT

[email protected]

2154997062

Sponsors and collaborators

Lead sponsor

AlloSource

Industry

Registry information

Official study title

A Prospective, Open Label, Single-Arm, Multi-Center Study Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee

Important dates

Study start
2024
Primary completion
2031
Study completion
2031
First posted
Jan 22, 2024
Registry last updated
Nov 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.